|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2.
|
Hu X, Li D, Zhang W, Zhou J, Tang B and Li
L: Matrix metalloproteinase-9 expression correlates with prognosis
and involved in ovarian cancer cell invasion. Arch Gynecol Obstet.
286:1537–1543. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Fidler IJ: The pathogenesis of cancer
metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev
Cancer. 3:453–458. 2003.
|
|
4.
|
Fishman DA, Liu Y, Ellerbroek SM and Stack
MS: Lysophosphatidic acid promotes matrix metalloproteinase (MMP)
activation and MMP-dependent invasion in ovarian cancer cells.
Cancer Res. 61:3194–3199. 2001.PubMed/NCBI
|
|
5.
|
Sourbier C: Ovarian cancer: emerging
molecular-targeted therapies. Biologics. 6:147–154. 2012.PubMed/NCBI
|
|
6.
|
Ledermann J, Harter P, Gourley C, et al:
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian
cancer. N Engl J Med. 366:1382–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Yamamoto N, Nokihara H, Yamada Y, et al: A
phase I, dose-finding and pharmacokinetic study of olaparib
(AZD2281) in Japanese patients with advanced solid tumors. Cancer
Sci. 103:504–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Campos SM and Ghosh S: A current review of
targeted therapeutics for ovarian cancer. J Oncol. 2010:1493622010.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kumagai T, Wakimoto N, Yin D, et al:
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid
(Vorinostat, SAHA) profoundly inhibits the growth of human
pancreatic cancer cells. Int J Cancer. 121:656–665. 2007.
View Article : Google Scholar
|
|
10.
|
Ramalingam SS, Parise RA, Ramanathan RK,
et al: Phase I and pharmacokinetic study of vorinostat, a histone
deacetylase inhibitor, in combination with carboplatin and
paclitaxel for advanced solid malignancies. Clin Cancer Res.
13:3605–3610. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Itamochi H: Targeted therapies in
epithelial ovarian cancer: molecular mechanisms of action. World J
Biol Chem. 1:209–220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Yap TA, Carden CP and Kaye SB: Beyond
chemotherapy: targeted therapies in ovarian cancer. Nature reviews
Cancer. 9:167–181. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Pautier P, Joly F, Kerbrat P, et al: Phase
II study of gefitinib in combination with paclitaxel (P) and
carboplatin (C) as second-line therapy for ovarian, tubal or
peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol.
116:157–162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Cohen M, Dromard M and Petignat P: Heat
shock proteins in ovarian cancer: a potential target for therapy.
Gynecol Oncol. 119:164–166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Behbakht K, Sill MW, Darcy KM, et al:
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation
of circulating tumor cells and tumor biomarkers in persistent and
recurrent epithelial ovarian and primary peritoneal malignancies: a
Gynecologic Oncology Group study. Gynecol Oncol. 123:19–26. 2011.
View Article : Google Scholar
|
|
16.
|
Huynh H, Teo CC and Soo KC: Bevacizumab
and rapamycin inhibit tumor growth in peritoneal model of human
ovarian cancer. Mol Cancer Ther. 6:2959–2966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Lord CJ and Ashworth A: Targeted therapy
for cancer using PARP inhibitors. Curr Opin Pharmacol. 8:363–369.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Liu Z, Zhu J, Cao H, Ren H and Fang X:
miR-10b promotes cell invasion through RhoC-AKT signaling pathway
by targeting HOXD10 in gastric cancer. Int J Oncol. 40:1553–1560.
2012.PubMed/NCBI
|
|
20.
|
Wotschofsky Z, Liep J, Meyer HA, et al:
Identification of metastamirs as metastasis-associated microRNAs in
clear cell renal cell carcinomas. Int J Biol Sci. 8:1363–1374.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
White NM, Khella HW, Grigull J, et al:
miRNA profiling in metastatic renal cell carcinoma reveals a
tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Zaravinos A, Radojicic J, Lambrou GI, et
al: Expression of miRNAs involved in angiogenesis, tumor cell
proliferation, tumor suppressor inhibition, epithelial-mesenchymal
transition and activation of metastasis in bladder cancer. J Urol.
188:615–623. 2012. View Article : Google Scholar
|
|
23.
|
Karsy M, Arslan E and Moy F: Current
progress on understanding microRNAs in glioblastoma multiforme.
Genes Cancer. 3:3–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Sasayama T, Nishihara M, Kondoh T, Hosoda
K and Kohmura E: MicroRNA-10b is overexpressed in malignant glioma
and associated with tumor invasive factors, uPAR and RhoC. Int J
Cancer. 125:1407–1413. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Myers C, Charboneau A, Cheung I, Hanks D
and Boudreau N: Sustained expression of homeobox D10 inhibits
angiogenesis. Am J Pathol. 161:2099–2109. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Gupta RA, Shah N, Wang KC, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Osborne J, Hu C, Hawley C, Underwood LJ,
O’Brien TJ and Baker VV: Expression of HOXD10 gene in normal
endometrium and endometrial adenocarcinoma. J Soc Gynecol Investig.
5:277–280. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Reddy SD, Ohshiro K, Rayala SK and Kumar
R: MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase
1 and regulates its functions. Cancer Res. 68:8195–8200. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Carrio M, Arderiu G, Myers C and Boudreau
NJ: Homeobox D10 induces phenotypic reversion of breast tumor cells
in a three-dimensional culture model. Cancer Res. 65:7177–7185.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 27:5287–5297. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Horiuchi A, Imai T, Wang C, et al:
Up-regulation of small GTPases, RhoA and RhoC, is associated with
tumor progression in ovarian carcinoma. Lab Invest. 83:861–870.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Chang S and Sharan SK: BRCA1 and
MicroRNAs: emerging networks and potential therapeutic targets. Mol
Cells. 34:425–432. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Bovicelli A, D’Andrilli G and Giordano A:
New players in ovarian cancer. J Cell Physiol. 226:2500–2504. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Asadollahi R, Hyde CA and Zhong XY:
Epigenetics of ovarian cancer: from the lab to the clinic. Gynecol
Oncol. 118:81–87. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Shahab SW, Matyunina LV, Hill CG, et al:
The effects of MicroRNA transfections on global patterns of gene
expression in ovarian cancer cells are functionally coordinated.
BMC Med Genomics. 5:332012. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Chen J, Wang L, Matyunina LV, Hill CG and
McDonald JF: Overexpression of miR-429 induces
mesenchymal-to-epithelial transition (MET) in metastatic ovarian
cancer cells. Gynecol Oncol. 121:200–205. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Lou Y, Yang X, Wang F, Cui Z and Huang Y:
MicroRNA-21 promotes the cell proliferation, invasion and migration
abilities in ovarian epithelial carcinomas through inhibiting the
expression of PTEN protein. Int J Mol Med. 26:819–827.
2010.PubMed/NCBI
|
|
39.
|
Li J, Liang S, Yu H, Zhang J, Ma D and Lu
X: An inhibitory effect of miR-22 on cell migration and invasion in
ovarian cancer. Gynecol Oncol. 119:543–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Siemens H, Jackstadt R, Hunten S, et al:
miR-34 and SNAIL form a double-negative feedback loop to regulate
epithelial-mesenchymal transitions. Cell Cycle. 10:4256–4271. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Kim NH, Kim HS, Li XY, et al: A
p53/miRNA-34 axis regulates Snail1-dependent cancer cell
epithelial-mesenchymal transition. J Cell Biol. 195:417–433. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Preis M, Gardner TB, Gordon SR, et al:
MicroRNA-10b expression correlates with response to neoadjuvant
therapy and survival in pancreatic ductal adenocarcinoma. Clin
Cancer Res. 17:5812–5821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Bloomston M, Frankel WL, Petrocca F, et
al: MicroRNA expression patterns to differentiate pancreatic
adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA.
297:1901–1908. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Teplyuk NM, Mollenhauer B, Gabriely G, et
al: MicroRNAs in cerebrospinal fluid identify glioblastoma and
metastatic brain cancers and reflect disease activity. Neuro Oncol.
14:689–700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Huse JT, Brennan C, Hambardzumyan D, et
al: The PTEN-regulating microRNA miR-26a is amplified in high-grade
glioma and facilitates gliomagenesis in vivo. Genes Dev.
23:1327–1337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Ciafre SA, Galardi S, Mangiola A, et al:
Extensive modulation of a set of microRNAs in primary glioblastoma.
Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Chisholm KM, Wan Y, Li R, Montgomery KD,
Chang HY and West RB: Detection of long non-coding RNA in archival
tissue: correlation with polycomb protein expression in primary and
metastatic breast carcinoma. PLoS One. 7:e479982012. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Niinuma T, Suzuki H, Nojima M, et al:
Upregulation of miR-196a and HOTAIR drive malignant character in
gastrointestinal stromal tumors. Cancer Res. 72:1126–1136. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Kogo R, Shimamura T, Mimori K, et al: Long
noncoding RNA HOTAIR regulates polycomb-dependent chromatin
modification and is associated with poor prognosis in colorectal
cancers. Cancer Res. 71:6320–6326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Geng YJ, Xie SL, Li Q, Ma J and Wang GY:
Large intervening non-coding RNA HOTAIR is associated with
hepatocellular carcinoma progression. J Int Med Res. 39:2119–2128.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Yang J, Mani SA, Donaher JL, et al: Twist,
a master regulator of morphogenesis, plays an essential role in
tumor metastasis. Cell. 117:927–939. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Ma L, Reinhardt F, Pan E, et al:
Therapeutic silencing of miR-10b inhibits metastasis in a mouse
mammary tumor model. Nat Biotechnol. 28:341–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
